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activating molecules such as LPS and poly I:C to TLRs
both on the cell surface and within cells) and as a signal
amplifier by moving TLRs into kinase-rich environment
of lipid raft microdomains (Figure 1). These speculations
are not entirely without clinical importance as we and
others have shown that kinase inhibitors and G protein
binding reagents may affect the production of cytokines
mediated by these CD14-related pathways (Lentschat
et al., 2005; Solomon et al., 1998).
Why is the nature of the ‘‘amplifying’’ effect of CD14
important? CD14, like TLRs, is a polymorphic protein,
and single nucleotide polymorphisms of CD14 have
been shown to predict susceptibility or resistance to
a variety of diseases. Furthermore, we and others have
demonstrated that src kinase inhibitors and G protein
binders may modulate CD14-associated responses.
Drugs that modulate the function of CD14 are possible,
but we need to understand how they might work both
intracellularly and extracellularly. The exciting new
studies of Lee et al. (2006) suggest that therapies target-
ing CD14 may also interfere with TLR3 activation by viral
nucleic acids, thus holding out the prospect these
agents may be effective in the control of viral as well
as bacterial diseases in which excess immune respon-
siveness damages the host.
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129An Unexpected Connection:
Lymph Node Lymphangiogenesis
and Dendritic Cell Migration
Migration of antigen-presenting dendritic cells (DCs)
through lymphatics to draining lymph nodes (LNs)
represents a key step in the initiation of an adaptive
immune response. In this issue of Immunity, Angeli
et al. (2006) provide the first evidence that remodeling
of the lymphatic network within LNs and in peripheral
tissues enhances DC migration after immunization
and that this process depends on the presence of B
cells within the LN.
For decades, the lymphatic vascular system has been
considered as a rather inert drainage system of the body,
primarily involved in transporting protein-rich fluid
and leukocytes from peripheral tissues to LNs and back
to the blood circulation. Only over the last years has
it become apparent that lymphatic vessels are actively
involved in many physiologic and pathologic pro-
cesses (Oliver and Detmar, 2002). In particular, remod-
eling of the lymphatic system by tumor-derivedlymphangiogenic factors actively promotes cancer me-
tastasis, and lymphangiogenesis also plays a major role
in the pathogenesis of various inflammatory conditions
(Alitalo et al., 2005). Recent studies have revealed
a close relationship between lymphangiogenesis and
immunity: inflammatory cells such as macrophages
produce lymphangiogenic factors (Cursiefen et al.,
2004) and might physically contribute to lymphatic ves-
sel formation (Maruyama et al., 2005). Furthermore, kid-
ney transplant rejection is frequently accompanied by
lymphangiogenesis (Kerjaschki et al., 2004), and the
chronic autoimmune disease psoriasis is characterized
by extensive lymphatic hyperplasia (Kunstfeld et al.,
2004). Although migration of antigen-presenting DCs
through lymphatics to draining LNs is an important step
in the initiation of an adaptive immune response, very lit-
tle is known about how lymphangiogenesis affects DC
migration.
In this issue of Immunity, Angeli et al. (2006) provide
the first evidence that remodeling of the lymphatic net-
work within the LN and in peripheral tissues enhances
DC migration to the draining LN after immunization with
complete Freund’s adjuvant (CFA). Surprisingly, the au-
thors find that, in mice, DC migration is not only en-
hanced from the local site of adjuvant injection into
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130Figure 1. B Cell-Induced Lymphangiogenesis in Activated Lymph Nodes Promotes Dendritic Cell Recruitment
Adjuvant-induced inflammation is known to enhance migration of DCs from the site of injection to the draining LN and to cause LN swelling.
Angeli et al. (2006) show that adjuvant-induced immunization is accompanied by massive remodeling of the nodal lymphatic architecture.
The lymphatic network expands not only at the site of adjuvant injection but also in distant, uninvolved tissue draining to the same node. The
lymphangiogenic response leads to enhanced recruitment of DCs (green) from the uninvolved periphery site. VEGF-A production by B cells
in the activated LN plays a key role in the induction of lymphangiogenesis and DC recruitment.the front footpad but also from apparently uninvolved
scapular skin, a tissue distant to the site of adjuvant in-
jection, that drains to the same LN (Figure 1). Although
their study does not formally show the mechanism
responsible for the enhanced accumulation of DCs in
inflamed LNs, an impressive series of data, which prac-
tically ruled out alternative explanations (e.g., alter-
ations in DC proliferation or survival, or in DC emigration
from the LN via the efferent lymphatics), suggest that
changes in the lymphatic network of the activated LN
lead to an increase in DC mobilization from the periph-
ery. The lymphatic vascular network was dramatically
expanded in LNs of immunized mice, as evidenced by
immunofluorescent staining for the lymphatic-specific
hyaluronan receptor LYVE-1. Lymphatic vessels were
not just passively dilated, but lymphatic endothelial
cells (LECs) were actively proliferating, as demon-
strated by enhanced labeling for the proliferation
marker Ki-67. Surprisingly, more lymphatic vessels
were also present at the peripheral, uninflamed site from
which enhanced DC mobilization was observed (Fig-
ure 1). Importantly, treatment with antibodies blockingeither VEGF receptor 2 (VEGFR-2) or VEGFR-3 led to
a reduction of the nodal lymphatic network and also
reduced overall LN cellularity and DC migration to the
activated LN.
In search of cellular components and mediators of the
observed lymphangiogenic response, Angeli et al.
(2006) found that this process highly depends on the
presence of B cells within the LN. Immunofluorescent
analysis revealed that VEGF-A expression colocalizes
with B cell follicles in activated LNs, and B cells could
be stimulated to secrete enhanced levels of VEGF-A in
vitro, suggesting an involvement of this B cell-derived
mediator in LN lymphangiogenesis and DC recruitment
(Figure 1). These results are in agreement with the
recent observation of LN lymphangiogenesis within
sentinel LNs of VEGF-A-overexpressing skin cancers,
which occurred even before these tumors metastasized
(Hirakawa et al., 2005). Although these findings were
explained by the passive drainage of tumor-derived
VEGF-A via lymphatic vessels, the results by Angeli
et al. raise the important issue of whether immune cells
might potentially also be involved in the mediation of
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131tumor-induced LN lymphangiogenesis. Interestingly,
blockade of VEGFR-3, a specific receptor for VEGF-C
and VEGF-D but not for VEGF-A, also diminished
immunization-induced lymphangiogenesis in the pres-
ent study. Together with the incomplete suppression
of LN lymphangiogenesis by blocking antibodies
against both VEGFR-2 and VEGFR-3, these results sug-
gest that lymphangiogenesis factors other than VEGF-A
might play an additional role.
As with other intriguing discoveries, these findings
raise further important questions: for instance, it re-
mains unclear at this time what signals mediate the ob-
served increase in lymphatic vessels in the periphery.
Does the presence of B cells in the draining LN or treat-
ment with antibodies blocking VEGFR-2 and VEGFR-3
also affect peripheral lymphatic vessels and thereby
DC migration? Although no signs of an inflammatory
response (e.g., infiltration of inflammatory cells or upre-
gulation of VCAM-1 on vascular endothelium) were
detectable in the ‘‘uninvolved’’ skin, it is impossible to
conclusively rule out that LECs at this site received ac-
tivating stimuli from circulating inflammatory mediators
generated at the site of adjuvant injection. However, this
uncertainty presently remains difficult to address,
because little is known about the mechanisms of LEC
activation, and no phenotypic characterization of acti-
vated LECs has been performed to date. It will also be
interesting to investigate in future studies whether the
observed expansion of the lymphatic network—both in
the LN and in the periphery—regresses once the inflam-
matory stimulus has been cleared or whether it persists
over time to allow more efficient DC migration and more
rapid initiation of an immune response in the case of
a subsequent exposure to antigen.
Enhancing DC migration from the site of injection or an-
tigen uptake to the draining LN is considered an important
strategy for improving overall efficacy of DC-based immu-
notherapy (Berger and Schultz, 2003). The idea suggested
by this study, that preconditioning of the lymphatic vascu-
lature could lead to a further improvement in DC mobiliza-
tion to the draining LN, is certainly intriguing. However, it
will remain to be seen whether the effect of LN lymphan-
giogenesis on DC recruitment is as strong in species
larger than mice, where the distance that DCs need to
migrate from a peripheral tissue to the activated, draining
LN is invariably much longer.
To date, research on DC migration from peripheral
tissues to draining LNs has mostly focused on
DC-expressed adhesion molecules and receptors(Randolph et al., 2005). The present study suggests that
activation of the lymphatic endothelium may similarly
affect DC migration. Clearly, there is a growing interest
in better understanding how DCs interact with LECs. In
this regard, new technologies such as two-photon mi-
croscopy, which has already been used to image DC mi-
gration within LNs, may soon also provide new insights
into how DCs migrate into and traffic within lymphatic
vessels (Halin et al., 2005). Such an approach might
eventually allow us to address a further question
brought up by this study, namely, at which anatomical
level (e.g., small peripheral lymphatics or larger collect-
ing vessels) the lymphatic vascular system regulates DC
migration.
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